Abstract
Late-gadolinium enhanced (LGE)-MRI has revealed atrial fibrotic remodeling in embolic stroke of undetermined source (ESUS) patients comparable to that observed in atrial fibrillation (AFib) patients. Here, we use computational modeling to understand why fibrosis in ESUS does not cause arrhythmia. Left atrial (LA) models were reconstructed via a standardized process and simulations were conducted to probe the fibrotic substrate’s capacity to sustain reentrant drivers (RD). RD-perpetuated arrhythmia was observed in 23/45 (51%) ESUS and 28/45 (62%) AFib models. LA models in which RDs were inducible had significantly more fibrosis than those which were non-inducible (16.8±5.04% vs. 10.19±3.14%; P<0.0001); however, between the specific subsets of inducible ESUS and AFib models, there was no difference in fibrosis burden (P=0.068). Thus, within our modeling framework, pro-arrhythmic properties of fibrosis in ESUS and AFib are indistinguishable, suggesting many ESUS patients have latent fibrotic substrate that may be a potential future source of arrhythmogenicity.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
n/a this study is not a clinical trial
Funding Statement
SFB is supported by a fellowship from the ARCS foundation. CHR is supported by a Medical Research Council Skills Development Fellowship (MR/S015086/1). SAN is supported by NIH R01-HL152256, ERC PREDICT-HF (864055), BHF (RG/20/4/34803), EPSRC (EP/P01268X/1), and the Wellcome Trust (203148/Z/16/Z). DT and WTL are co-PIs for the ARCADIA trial (NIH 5-U01-NS095869), which receives in-kind study drug from the BMS-Pfizer Alliance and ancillary funding from Roche Diagnostics. NA is supported by John Locke Charitable Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients were recruited to undergo cardiac LGE-MRI from the University of Washington (Seattle, WA) and Klinikum Coburg (Coburg, Germany) between July 2016 and June 2019. It was approved by the Institutional Review Board (IRB) of the University of Washington (UW) and the Ethikkommission der Bayerischen Ländesärztekammer München, Bayern, Deutschland; all participants provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interests: None declared
Manuscript reordered to place Results before Methods; other minor cosmetic revisions to text to correct typos, make text more concise, etc.
Data Availability
Following publication, relevant data will be made available by the authors in response to reasonable requests for non-commercial reuse upon approval from the relevant Independent Ethics Committee(s).
